Table 2.
Variable | CKD Stage 1 (n=425) | CKD Stage 2 (n=616) | CKD Stage 3 (n=231) | |||
---|---|---|---|---|---|---|
Tolvaptan (n=267) | Placebo (n=158) | Tolvaptan (n=402) | Placebo (n=214) | Tolvaptan (n=147) | Placebo (n=84) | |
Rate of TKV growth, %/yr | 3.1±5.2 | 5.1±4.6 | 2.1±5.0 | 5.3±5.0 | 4.2±7.5 | 7.2±7.0 |
Treatment effect (95% CI), %/yr | −1.99 (−2.85 to −1.13) | −3.12 (−3.93 to −2.31) | −2.61 (−4.08 to −1.17) | |||
P value | <0.001 | <0.001 | <0.001 | |||
Relative treatment effect, % | 40.4 | 60.4 | 39.8 |
Values expressed with a plus/minus sign are the mean±SD. TKV, total kidney volume; 95% CI, 95% confidence interval.